187 results on '"Cavallone, D."'
Search Results
2. Quantitative HBV/HDV markers help to distinguish different clinic/virologic phases of chronic hepatitis delta
3. HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling
4. OC.12.1 QUANTITATIVE HBV/HDV MARKERS HELP TO DISTINGUISH DIFFERENT CLINIC/VIROLOGIC PHASES OF CHRONIC HEPATITIS DELTA
5. Cancer cells and tumor vasculature dynamics analyzed by bio-mathematical modeling in HCC patients with different response to TKIs, TACE and TARE
6. Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients
7. AF.88 THREE HBSAG KINETIC PROFILES IN HBEAG NEGATIVE INFECTION AND CHRONIC HEPATITIS ARE ASSOCIATED WITH DIFFERENT CHANCES OF HBSAG CLEARANCE
8. OC.04.9 A SINGLE CENTER, LARGE LONG TERM COHORT STUDY OF THE RELATIONS BETWEEN MUTATIONS IN BASIC-CORE-PROMOTER AND PRE-C REGIONS OF HEPATITIS B VIRUS DNA AND CLINICPATHOLOGIC OUTCOME OF HBEAG-NEGATIVE/ANTI-HBEPOSITIVE PHASE
9. AF.89 CHANGING DEMOGRAPHIC-CLINIC-PATHOLOGIC PROFILES OF NEWLY DIAGNOSED CARRIERS OF CHRONIC HEPATITIS B VIRUS INFECTION ACROSS TWO DECADES: A SINGLE ITALIAN REFERENCE CENTER REPORT
10. AF.84 BIOIMAGING, BIOCHEMICAL AND GENETIC MARKERS TO STRATIFY PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CLINICAL PRACTICE: A SINGLE CENTER COHORT STUDY
11. AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB
12. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis
13. Modeling hepatocellular carcinoma cells dynamics by serolo-gical and imaging biomarkers in patients with response to sorafenib and/or regorafenib
14. Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single regional reference center report
15. A single center, large long-term cohort study of the relations between mutations in Basic-Core-Promoter and pre-C regions of Hepatitis B virus DNA and clinic-pathologic outcome of HBeAg-negative/anti-HBe-positive phase
16. T06.01.21 PNPLA3 COULD HELP THE CLINICIANS TO INDIVIDUATE NAFLD SUBJECTS AT MAJOR RISK OF DISEASE PROGRESSION: A SINGLE CENTER CHOHORT STUDY
17. T06.01.10 DATA DRIVEN MODEL OF NEOPLASTIC CELLS DYNAMICS BY CIRCULATING AND IMAGING BIOMARKERS OF HEPATOCELLULAR CARCINOMA: A PROMISING TOOL FOR INDIVIDUALIZED THERAPY
18. T06.01.22 THREE HBSAG KINETIC PROFILES IN HBEAG NEGATIVE INFECTION AND CHRONIC HEPATITIS ARE ASSOCIATED WITH DIFFERENT CHANCES OF HBSAG CLEARANCE
19. HBsAg clearance in HBeAg negative infection and treated chronic hepatitis B is associated with different HBsAg kinetics
20. OC.05.3: MODELING CANCER CELLS AND TUMOR VASCULATURE DYNAMICS BY SERUM BIOMARKERS IN HCC PATIENTS WITH DIFFERENT RESPONSE TO TKIS, TACE AND TARE SUGGESTS A SYNERGISTIC EFFECT OF SYSTEMIC AND ENDOVASCULAR TREATMENTS.
21. P.04.6 MODELING THE TIME-RELATED FLUCTUATIONS OF AFP AND PIVKA-II SERUM LEVELS IN PATIENTS WITH CIRRHOSIS UNDERGOING SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
22. P.04.12 HBSAG SERUM LEVEL AND HBV GENE S QUASISPECIES IN THE HBEAG NEGATIVE PHASE OF CHRONIC GENOTYPE D HBV INFECTION
23. Cover Image
24. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection
25. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
26. Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in single patients with cirrhosis undergoing surveillance for hepatocellular carcinoma
27. Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma
28. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy
29. Low viremic HBeAg negative HBsAg carriers: Clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers
30. In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy
31. Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B
32. IDENTIFICATION OF LAMIVUDINE RESISTANT HBV STRAIN RT204V IN ACUTE HEPATITIS B IN ITALY
33. Etiology of chronic liver disease and HCC biomarkers
34. MiR-B-index: A candidate bio-marker to identify the immune control of HBV infection in chronic hepatitis B patients treated with nucleos(t)ide-analogues
35. FRI-166 - Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in single patients with cirrhosis undergoing surveillance for hepatocellular carcinoma
36. THU-359 - National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
37. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
38. P0635 : Chronic hepatitis B treatment individualization by means of serum HBsAg and Mir-B-Index kinetics
39. Chronic hepatitis B treatment individualization by means of serum HBsAg and MiR-B-Index kinetics
40. Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease
41. P1202 EARLY PREDICTION OF SUSTAINED VIROLOGIC RESPONSE BY HCV CORE ANTIGEN KINETICS IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON PLUS RIBAVIRIN
42. P688 LONG-TERM OUTCOME OF INACTIVE AND LOW VIREMIC HBeAg NEGATIVE ACTIVE CARRIERS: BENIGN ONE DIRECTION TRANSITION TOWARDS SPONTANEOUS HBsAg CLEARANCE
43. Long-term outcome of inactive and low viremic HBeAg negative active carriers: Benign one direction transition towards spontaneous HBsAg clearance
44. Early prediction of sustained virologic response by HCV Core Ag kinetics in chronic hepatitis C patients treated with Peginterferon plus Ribavirin
45. FRI-112 - Mir-B-Index: A Candidate Bio-Marker to Identify the Immune Control of HBV Infection in Chronic Hepatitis B Patients Treated with Nucleos(t)ide-Analogues
46. 251 THERAPY WITH T CELL RECEPTOR GENE MODIFIED T CELLS TARGETING HBsAg-PRODUCING HCC METASTASES
47. OC-25 Bio-mathematical modelling provides the most accurate selection of HCV-G1 patients for triple-therapy
48. T-06 Early HCV-Core-Ag kinetics predict sustained virologic response in chronic hepatitis C patients treated with standard of care
49. 540 IDENTIFICATION OF LAMIVUDINE RESISTANT HBV STRAIN RT204V/I IN ACUTE HEPATITIS B IN ITALY
50. P.04.1 IL28B POLYMORPHISM IN CHRONIC HBV INFECTION: THE CC ALLELE DOES NOT CORRELATE WITH THE PHASE OF THE INFECTION NOR WITH HBSAG CLEARANCE IN IFN TREATED PATIENTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.